Wall Street Zen upgraded shares of Arcturus Therapeutics ( NASDAQ:ARCT – Free Report ) from a sell rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.
A number of other equities research analysts also recently commented on ARCT. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Thursday, September 24th. Citigroup raised shares of Arcturus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $8.00 to $20.00 in a research report on Thursday, September 24th. Leerink Partners lifted their price objective on shares of Arcturus Therapeutics from $13.00 to $19.00 and gave the stock an “outperform” rating in a research report on Friday, October 9th. BTIG Research lowered their target price on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, September 24th. Finally, Roth Capital reissued a “buy” rating and issued a $41.00 target price on shares of Arcturus Therapeutics in a report on Wednesday, September 2nd. Two analysts have rated the stock with a Strong Bu...